Evidence map›Paper›PMID 34436219›Full record

ArticleMedicines (Basel, Switzerland)2021

Comparison of G8 and ISAR Screening Results in Geriatric Urology.

Jobar Bouzan, Boris Stoilkov, Spyridon Nellas, Marcus Horstmann

Open access · goldAbstract read
In one paragraph

Article in Medicines (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Item analysis of G8 screening in uro-oncologic geriatric patients.International urology and nephrology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jobar BouzanDepartment of Urology, Helios Hospital St. Josefshospital, Krefeld Uerdingen, Kurfürstenstr. 69, 47829 Krefeld, Germany.
Boris StoilkovDepartment of Urology, Helios Hospital St. Josefshospital, Krefeld Uerdingen, Kurfürstenstr. 69, 47829 Krefeld, Germany.
Spyridon NellasDepartment of Urology, Helios Hospital St. Josefshospital, Krefeld Uerdingen, Kurfürstenstr. 69, 47829 Krefeld, Germany.
Marcus HorstmannDepartment of Urology, Helios Hospital St. Josefshospital, Krefeld Uerdingen, Kurfürstenstr. 69, 47829 Krefeld, Germany.ORCID 0000-0001-5420-754X
Helios Klinikum Krefeld · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe G8 and ISAR scores are two different screening tools for geriatric risk factors and frailty. The aim of this study was to compare the G8 and ISAR screening results in a cohort of urogeriatric patients to help clinicians to better understand and choose between the two tests.

methodsWe retrospectively evaluated 100 patients at the age of 75 and above who were treated for different urological conditions. All routinely and prospectively underwent G8 and ISAR screening tests. A G8 score ≤ 14 and an ISAR score > 2 were considered positive. The results for the two tests were compared and correlated to clinical data.

resultsThe mean age of the patients was 83 y (min. 75-max. 101); 78 of the patients were male, while 22 were female; 58 of the patients were G8-positive, while 42 were G8-negative; and 24 were ISAR-positive, while 76 ISAR were negative. All the ISAR-positive patients were also G8-positive. There was a significant negative correlation between the G8 and ISAR scores (r = -0.77,

conclusionBoth tests are significantly correlated with each other and to clinical data related to geriatric frailty. However, the G8 score has a much higher rate of positive tests, which limits its use in daily routine, and the ISAR score is therefore preferable. For "fit" geriatric patients, however, a negative G8 score can be of great use as a confirmatory test for further decision making.

Indexed as

geriatric assessment G8 scoregeriatric screeninggeriatric urologyISAR score

Identifiers

PMID34436219
PMCPMC8398154
OpenAlexW3183422470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.